Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial.
Addiction
; 107(7): 1297-306, 2012 Jul.
Article
in En
| MEDLINE
| ID: mdl-22221594
ABSTRACT
AIMS:
Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double-blind, placebo-controlled out-patient trial tested topiramate for treating methamphetamine addiction.DESIGN:
Participants (n = 140) were randomized to receive topiramate or placebo (13 weeks) in escalating doses from 25 mg/day [DOSAGE ERROR CORRECTED] to the target maintenance of 200 mg/day in weeks 6-12 (tapered in week 13). Medication was combined with weekly brief behavioral compliance enhancement treatment.SETTING:
The trial was conducted at eight medical centers in the United States.PARTICIPANTS:
One hundred and forty methamphetamine-dependent adults took part in the trial. MEASUREMENTS The primary outcome was abstinence from methamphetamine during weeks 6-12. Secondary outcomes included use reduction versus baseline, as well as psychosocial variables.FINDINGS:
In the intent-to-treat analysis, topiramate did not increase abstinence from methamphetamine during weeks 6-12. For secondary outcomes, topiramate reduced weekly median urine methamphetamine levels and observer-rated severity of dependence scores significantly. Subjects with negative urine before randomization (n = 26) had significantly greater abstinence on topiramate versus placebo during study weeks 6-12. Topiramate was safe and well tolerated.CONCLUSIONS:
Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent.
Full text:
1
Database:
MEDLINE
Main subject:
GABA Agents
/
Excitatory Amino Acid Antagonists
/
Amphetamine-Related Disorders
/
Fructose
/
Methamphetamine
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2012
Type:
Article